Navigation Links
Cambrex Reports Fourth Quarter and Full Year 2009 Results
Date:2/10/2010

n two large capital projects for which the majority of work has since been completed.  

Steven M. Klosk, President and Chief Executive Officer, said, "We are pleased to finish 2009 at the high end of our prior earnings guidance, with just over $47 million in EBITDA.  We successfully managed working capital and expense levels throughout the business and reduced net debt by nearly $23 million during the year.

"As we entered 2009 the macro-economy suggested a conservative approach that led us to focus on reducing costs and maximizing cash flow.  While the outlook for the economy appears to have stabilized as we start 2010, our smaller customers continue to face a difficult funding environment and pricing pressures continue to exist in most product categories.  The 2010 forecasts for certain of our larger products are lower than we expected, and in some cases lower than 2009, for a variety of reasons.  We renegotiated an extension of an important contract for certain drug delivery products during the fourth quarter, and made price and volume concessions in order to maintain the majority of the share of this business over the next three years.  These are key factors contributing to our guidance of flat to lower sales and profits for 2010.

"We have opportunities to grow revenues through the advancement of projects in our pipeline of late stage development products, within our controlled substances and drug delivery categories and through the launch of new generic APIs.  However, we are convinced that we need to invest more aggressively, both internally and externally, in niche markets, novel technologies, and new geographies that generate sustainable growth.  Of course, we will continue to identify ways to further reduce costs and increase cash flow as we focus on growing the business."

'/>"/>

SOURCE Cambrex Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15

Related biology technology :

1. Cambrex Presentation at the JPMorgan Healthcare Conference to be Webcast
2. Cambrex to Announce Fourth Quarter and Full Year 2007 Financial Results on February 14, 2008
3. Cambrex Appoints Steven M. Klosk as President and CEO
4. Cambrex Reports Third Quarter 2008 Results
5. Cambrex Receives Notice Regarding NYSE Listing
6. Cambrex Reports First Quarter 2009 Results
7. Cambrex Continuous-Flow Microwave-Assisted Organic Synthesis Technology Nominated for 2009 Innovations Award
8. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
9. QMed, Inc. Reports July Medicare SNP Enrollments
10. Phlo Affiliate Reports Expanded Coverage to Oregon Border
11. Healthcare Technologies Reports Loss for 2007 Second Quarter & Six Months Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2014)... 2014 Myriant Corporation, a global ... a distribution agreement with Azelis Group, a specialty ... bio-succinic acid in the Nordics, Benelux, France, Iberia, ... in the industrial and base chemicals markets. , ... a far-reaching chemical portfolio with extensive distribution networks ...
(Date:9/2/2014)... 2, 2014  Synthetic Biologics, Inc. (NYSE MKT: ... drug candidates targeting specific pathogens that cause serious ... its final preclinical toxicology study of SYN-004. Per ... bridging study was required to move the Company,s ... the devastating effects of Clostridium difficile (C. ...
(Date:9/2/2014)... Victoria, Australia (PRWEB) September 02, 2014 ... provide a cure for chronic tinnitus are seeking support ... run on the Indiegogo platform ( http://igg.me/at/tinaway ), was ... to be a therapeutic ‘mHealth’ app and is based ... brainchild of a team of biomedical and software engineers, ...
(Date:8/31/2014)... September 01, 2014 Available spectra ... needs for research and cultivation of a wide ... Valoya’s proprietary LEDs with proven patented and pending ... uncompromised light uniformity in critical applications in contrast ... LEDs. , “Our customers have a large variety ...
Breaking Biology Technology:Myriant and Azelis Sign European Distribution Agreement for Bio-Succinic Acid 2Synthetic Biologics to Initiate Clinical Trials of SYN-004 in 4Q 2014 to Prevent Potentially Deadly C. difficile Infections 2Synthetic Biologics to Initiate Clinical Trials of SYN-004 in 4Q 2014 to Prevent Potentially Deadly C. difficile Infections 3Synthetic Biologics to Initiate Clinical Trials of SYN-004 in 4Q 2014 to Prevent Potentially Deadly C. difficile Infections 4Synthetic Biologics to Initiate Clinical Trials of SYN-004 in 4Q 2014 to Prevent Potentially Deadly C. difficile Infections 5tinAway Pty. Ltd. launch a crowdfunding campaign to fund a clinical trial of tinAway, a new potential cure for chronic tinnitus 2tinAway Pty. Ltd. launch a crowdfunding campaign to fund a clinical trial of tinAway, a new potential cure for chronic tinnitus 3tinAway Pty. Ltd. launch a crowdfunding campaign to fund a clinical trial of tinAway, a new potential cure for chronic tinnitus 4tinAway Pty. Ltd. launch a crowdfunding campaign to fund a clinical trial of tinAway, a new potential cure for chronic tinnitus 5
... Goal Is to Lower the Cost of Genome ... Information Universally Available for Routine Medical Care-PHILADELPHIA, Feb. ... whole genome imaging and analysis platforms for biomedical ... that its low-cost nanofluidic genome analysis technology, along ...
... 24 Environment of Care managers can ... achieve and maintain their organization,s environment of care ... series of brief, web-based audio interviews with EC experts ... or download at http://www.eheinc.com/ec_bits.htm feature expert advice ...
... ABBOTT PARK, Ill., Feb. 24 Abbott ( ... Healthcare Conference on Tuesday, March 10, 2009. Thomas ... officer, will make a formal presentation on the company ... the presentation will be accessible through Abbott,s Investor Relations ...
Cached Biology Technology:BioNanomatrix's Revolutionary Whole Genome Analysis Platform Named to MIT Technology Review's Annual 10 Emerging Technologies List 2BioNanomatrix's Revolutionary Whole Genome Analysis Platform Named to MIT Technology Review's Annual 10 Emerging Technologies List 3Web-based Audio Interviews Keep Environment of Care Managers Up-to-Date on Key EC Compliance Issues 2
(Date:9/2/2014)... issue of The FASEB Journal , ... the leading cause of blindness in adults, diabetic ... advance involves quantifying the early molecular changes caused ... Using new probes developed by scientists, they were ... diabetic retinopathy. , "My goal is to establish ...
(Date:9/2/2014)... D.C., September 2, 2014 A study published ... Journal of the American Academy of Child and ... diagnosed with a psychiatric diagnosis had an increased ... to antipsychotics. , Using data from the nationwide ... Dr. Ren Ernst Nielsen, Psychiatry, Aalborg University Hospital, ...
(Date:9/2/2014)... Bavaria, the Tithonian Konservat-Lagersttte of lithographic limestone is ... of emblematic fossils from that area (for example, ... found fossil insects in the French equivalent of ... species representing the oldest known water treader. , ... Bavarian outcrops, fewer fossils have been obtained from ...
Breaking Biology News(10 mins):Molecular probes permit doctors to detect diabetic retinopathy before vision fails 2Risk of diabetes in children and adolescents exposed to antipsychotics 2Exceptionally well preserved insect fossils from the Rhône Valley 2
... perennially covered in ice. It is exposed to severe ... and, during the winter, 24-hour darkness. But, for the ... To study them, Dr. Rachel Morgan-Kiss from the University ... to sample the ice-covered lake. The article describing her ...
... the most valuable possessions in the most secure safes, ... at the European Molecular Biology Laboratory,s European Bioinformatics Institute ... Nature , shows that bacteria have evolved a ... reducing the risk of self-destruction. The findings answer a ...
... of Gothenburg, Sweden, have identified the genetic variations ... in Nature Genetics and involving leading researchers ... facts that women with a higher proportion of genetic ... percent increased fracture risk. Osteoporosis is a common ...
Cached Biology News:Research on carbon-consuming life-forms in Antarctica published in JoVE 2A matter of priorities 2Scientists have discovered genes that increase the risk of osteoporosis and fractures 2
Extra Large bottle for hybridization 300 x 70mm...
Request Info...
... Microtube Rotor is TWO ROTORS in ONE! ... You can spin both 1.5 - ... polypropylene rotor design provides excellent chemical resistance ... rotors are fully compatible with common decontamination ...
... Wellpro 384, compatible ... automated liquid handling system ... quickly and accurately prepares ... dilutions. The Wellpro ...
Biology Products: